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URL: http://www.ucd.ie/sbbs/ (J. Crean).We describe the activation of Wnt signalling in mesangial cells by CCN2. CCN2 stimulates phosphor-
ylation of LRP6 and GSK-3b resulting in accumulation and nuclear localisation of b-catenin, TCF/LEF
activity and expression of Wnt targets. This is coincident with decreased phosphorylation of b-cate-
nin on Ser 33/37 and increased phosphorylation on Tyr142. DKK-1 and LRP6 siRNA reversed CCN2’s
effects. Microarray analyses of diabetic patients identiﬁed differentially expressedWnt components.
b-Catenin is increased in type 1 diabetic and UUOmice and in in vitromodels of hyperglycaemia and
hypertension. These ﬁndings suggest that Wnt/CCN2 signalling plays a role in the pathogenesis of
diabetic nephropathy.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Diabetic nephropathy (DN) is a debilitating progressive disease
arising from long term complications of diabetes [1]. The hallmark
of DN is glomerulosclerosis due to accumulation of extracellular
matrix (ECM) [2]. This ultimately causes mesangial expansion
and damage to the glomerular basement membrane, leading to
proteinuria [3]. Mediators of mesangial dysfunction include oxida-
tive stress [4], glucose [3], TGFb [5], advanced glycation end prod-
ucts (AGEs) [6] and glomerular hypertension [7]. A number of
recent reports have highlighted a role for Wnt signalling in the
pathogenesis of DN [8–10]. Importantly, LEF-1, the nuclear
transcription factor regulated by Wnt, promotes epithelial to
mesenchymal transition (EMT) when its activity is triggered by
b-catenin [11]. Mesangial cells cultured in high glucose were
shown to be resistant to Akt-dependent apoptosis in the presence
of a Wnt ligand and b-catenin nuclear localisation [8]. It is in this
context, that Wnt pathways are increasingly seen as viable targets
for intervention in the treatment of renal ﬁbrosis. Indeed, the ren-chemical Societies. Published by Eoprotective effects of many current therapies are thought to be
mediated, in part, via modulation of Wnt signalling [12].
Evidence suggests a complex relationship between connective
tissue growth factor/CCN family protein 2 (CTGF/CCN2) and the
Wnt pathway [13–16]. It was demonstrated in Xenopus laevis em-
bryos that CCN2 modulated Wnt signalling by binding to LRP5/6
[15]. Subsequently a number of studies have demonstrated CCN2’s
interaction with LRP6, while Wnt ligands increase CCN protein
expression. A relationship that contributes to increased ﬁbrosis
may exist between the Wnts and TGFb/smad signalling pathways
[17–19].
Here we show that CCN2 activates canonical Wnt signalling in
human mesangial cells; CCN2 causes nuclear accumulation of
b-catenin and TCF/LEF transcriptional activity. We also demon-
strate that CCN2 requires the LRP6 receptor to activate Wnt signal-
ling; treatment with DKK-1, the endogenous LRP6 receptor
antagonist, and LRP6 knockdown ameliorate CCN2 induced
responses. Our studies in animal models of diabetes and in patients
suffering from long term complications of diabetic nephropathy
highlight signiﬁcant alterations in Wnt related gene expression,
in particular increased expression of b-catenin. The observation
that CCN2 can interact with Wnt leads us to propose that the acti-
vation of Wnt pathways by CCN2 has pathophysiological signiﬁ-
cance during the initiation and progression of DN.lsevier B.V. All rights reserved.
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Fig. 1. CCN2 activates canonical Wnt signalling in human mesangial cells. Primary human mesangial cells were grown to 90% conﬂuency and serum starved for 24 h prior to
stimulation with recombinant human CCN2 (25 ng/ml). (A, B) Whole cell lysates were analysed by Western blot using the speciﬁc antibodies indicated (C). Cells were co-
transfected with the reporter Topﬂash or the mutated TCF/LEF reporter Fopﬂash and 2 lg of wildtype CCN2. Promoter reporter activity was measured using a dual luciferase
kit (Promega). All results are representative of at least three individual experiments.
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2.1. Animals
Procedures were licensed by the Irish Department of Health and
Children and approved by the UCD Animal Research Ethics Com-
mittee. Seven- to ten-week-old male C57Bl/6J mice were divided
into two groups: A, treated with streptozotocin (STZ) dissolved in
100 mmol/l citrate buffer, pH 4.5; or B, citrate buffer alone, follow-
ing AMDCC protocols (http://www.amdcc.org). Diabetes was con-
ﬁrmed by two consecutive daily measurements of fasting blood
glucose >15 mmol/l 2 weeks after injection. For unilateral ureteral
obstruction (UUO), male C57Bl/6J mice aged 10–12 weeks were
placed into two groups, UUO and sham-operated. The UUO group
was anaesthetized, received midline laparotomy and identiﬁcationwith ligation of the left ureter. The sham group had the left ureter
identiﬁed, manipulated but not ligated. On day 10, mice were
harvested and UUO was conﬁrmed by dilation of the renal pelvis.
Organs were perfused with heparinised saline and the left kidney
excised. The renal capsule was removed and the kidney ﬁxed in
10% formalin.
2.2. Tissue culture
Primary human mesangial cells (Lonza) were cultured in
MCDB-131, HeLa cells in MEM, both supplemented with 10% FBS,
L-glutamine and penicillin/streptomycin. Cells were maintained
at 5% CO2, 37 C and starved for 24 h prior to stimulation.
CCN2, N-half and C-half mutants were expressed and puriﬁed































CTGF (25 ng/ml, 3 hours)
Actin /β catenin
Actin /β catenin
Fig. 2. CCN2 stimulates nuclear accumulation of b-catenin and increased expression of b-catenin-transcriptionally regulated targets. Cells were grown to 90% conﬂuency and
serum starved for 24 h prior to stimulation with recombinant human CCN2 (25 ng/ml) and/or deletion mutants (N-half, C-half). (A, B) Whole cell lysates were analysed by
Western blot using the speciﬁc antibodies indicated. (C) Cells were ﬁxed using standard techniques and probed using speciﬁc antibodies to b-catenin. F-actin was visualised
with Alexa488 conjugated phallodin. Results are representative of at least three individual experiments.
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Osmotic control media was made iso-osmolar with the addition
of mannitol (30 mM). Cells were cultured on BioFlex six well
laminin-coated culture plates (Dunn Labortechnik GmbH) and
subjected to repeated stretch/relaxation cycles by mechanical
deformation (60 cycles/min, 8% uniaxial elongation) for up to
48 h.
2.3. RNAi Interference
Cells were transfected with 2 lM LRP6 siRNA or scrambled
siRNA, (Dharmacon ON-TARGET/Non-targeting Pool. D-001810-
10-20), and 6 ll of Fugene HD™ (Roche). Knockdown of LRP6
was conﬁrmed by Western blot. When cells reached 70% conﬂu-
ency, a migration assay was performed.
2.4. Electrophoresis and Western blotting
Total protein was separated by SDS–PAGE, transferred to nitro-
cellulose and probed with antibodies to phospho GSK-3b (Ser 9)
(1:1000, Cell Signaling Technologies), phospho b-catenin (Ser 33/
45) (1:500, Abcam), b-catenin (1:1000, Cell Signaling Technolo-gies), phospho LRP6 (Ser 19) (1:1000, Cell Signaling Technologies),
total LRP6 (1:1000, Cell Signaling Technologies), Cyclin D (1:1000),
c-myc (1:1000, Cell Signaling Technologies), b-actin (1:20,000, Sig-
ma) and Lamin (1:8000, Cell Signaling Technologies). Proteins were
visualised with HRP conjugated secondary antibodies using lumi-
nol (Santa Cruz).
2.5. Luciferase assay
Cells were co-transfected with the reporter Topﬂash or the mu-
tated TCF/LEF reporter Fopﬂash and 2 lg of wildtype CCN2 plasmid
using Fugene HD™. After 24 h, promoter reporter activity was
measured using a dual luciferase kit (Promega).
2.6. Immunocytochemistry
Cells were ﬁxed using standard techniques and probed using
speciﬁc antibodies to b-catenin (1:100, Millipore). F-Actin was vis-
ualised with Alexa488 conjugated phallodin. b-Catenin was de-
tected with Alexa594 conjugated anti mouse antibodies (1:1000,
Molecular Probes) and images captured using a Zeiss Axioscope
equipped with an Axiocam and Axiovision 4.1.
Phospho LRP6 (Ser 1490)
Total LRP6
















































Control CTGF 25ng/ml DKK-1 100 ng/ml CTGF/DKK-1
*
*p<.0001





Fig. 3. CCN2 activation of canonical Wnt signalling requires theWnt co-receptor LRP6. (A) Cells were grown to 90% conﬂuency and serum starved for 24 h prior to stimulation
with recombinant human CCN2 (25 ng/ml). Whole cell lysates were analysed by Western blot using antibodies speciﬁc for LRP6 and phospho LRP6 (Ser 1490). (B, C) Cells
were allowed to reach 70% conﬂuency and a scratch wound applied. Cells were pre-treated with 100 ng/ml of DKK-1 for 1 h then stimulated with 25 ng/ml of CCN2 for 24 h.
(D) A 96 well plate was coated with CCN2 (25 ng/ml) and/or DKK-1 (100 ng/ml). Cells were seeded for 3 h and ﬁxed with 3.7% paraformaldehyde. Nuclei were stained with
Hoescht 33258 and visualised using a Zeiss Axioscope with Axiovision 4. Results are representative of at least three individual experiments.
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Immunohistochemistrywasperformedonparafﬁnembeddedkid-
ney sections. Brieﬂy, post-mortem, mouse kidneys were ﬁxed in situ
using 4% (wt/vol) paraformaldehyde, and 3-lm sections stainedwith
anti-b-catenin (Millipore) and visualised with alkaline phosphatase.2.8. Cell migration
Cells were allowed to reach 70% conﬂuency and a scratch
wound applied. Cells were pre-treated with DKK-1 for 1 h then
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Fig. 4. siRNA knockdown of LRP6 inhibits CCN2 mediated cell migration (A, B). Cells were transfected with LRP6 siRNA or scrambled siRNA, once cells had reached 70–80%
conﬂuency a migration/wound assay was carried out as previously (C). Knockdown of LRP6 was conﬁrmed by Western blot.
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A 96 well plate was coated with CCN2 (25 ng/ml) and/or DKK-1
(100 ng/ml). Cells were seeded for 3 h and ﬁxed with 3.7% parafor-
maldehyde. Nuclei were stained with Hoescht 33258 and visual-
ised using a Zeiss Axioscope.
2.10. Microdissection and RNA isolation
Cortical tissue segments were microdissected under and total
RNA was isolated using a silica-gel based isolation protocol (Qia-
gen) and diluted in 30 ll RNase-free water. RNA quality and quan-
tity was assessed on a Bioanalyzer (Agilent Technologies).
2.11. Microarray analysis
Three hundred to eight hundred nanograms of RNA from living
donor (n = 3), cadaveric donor (n = 4), DN (n = 13), and MCD (n = 4)
was reverse-transcribed using SuperScript II (Invitrogen) and T7-
(dT)24. Second-strand synthesis was performed at 16 C for 2 h,
using DNA Polymerase I, DNA ligase, RNase H (Roche, 1 U/ll) and1X second-strand buffer. Double-stranded cDNA was blunt-ended
using T4 DNA polymerase, puriﬁed by phenol/chloroform extrac-
tion and transcribed for 16 h at 37 C in the presence of biotin
labeled-ribonucleotides, using the BioArray HighYield RNA tran-
script labeling kit (Enzo Laboratories). The biotin-labeled cRNA
was puriﬁed using RNeasy mini-column followed by a quality
check using the Bioanalyzer. The fragmentation, hybridization,
staining and imaging was performed according to the Affymetrix
guidelines.
2.12. Bioinformatic and data analysis
Image ﬁles were obtained through Affymetrix GeneChip soft-
ware (MAS5). Subsequently, robust multichip analysis (RMA) was
performed using RMA express. For each in vivo sample, an average
RMA value was computed for duplicate microarrays and to ensure
the average was statistically representative a t-test and P value
were generated. Only those genes with a P value of 60.01 were in-
cluded in subsequent analyses. Thereafter, expression data were
compared to control and signal log ratio used to generate a heat
map using Heat Map Builder.
Fig. 5. Wnt pathway and target genes are differentially expressed in renal biopsies (A), animal models of renal disease (B, C) and in vitro cell models of hypertension and
hyperglycaemia (D). (A) Microarray analysis of patient samples collected through the European Renal cDNA Biopsy Bank identiﬁes differential expression of several key
components of Wnt signalling. (B, C) Immunohistochemistry was performed on parafﬁn embedded kidney sections from diabetic and UUO mice. (D) Western blots were
performed on whole cell lysates from mesangial cells subjected to cyclic mechanical strain for 48 h (upper panel) or cultured in 30 mM glucose for up to 8 h (lower panels).
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The nature of its structural organisation has led to the emerging
view that CCN2 functions as a matricellular regulator. Supporting
this hypothesis, CCN2 modulates a variety of cell signalling path-
ways and receptors including LRP5/6 [21] TrKA [22], b1 integrins
[23] and b3 integrins [24]. Our studies elaborate a role for CCN2
as an activator of the canonical Wnt pathway in human mesangial
cells. Treatment of mesangial cells with CCN2 induced phosphory-
lation of GSK3b on the inhibitory residue serine 9 (Fig. 1A) and in-
creased levels of b-catenin, consistent with stabilisation associated
with activation of canonical Wnt pathways. This was characterised
by decreased phosphorylation of b-catenin on Ser 33/37 and an in-
crease on Tyr142, markers for degradation and nuclear accumula-
tion, respectively (Fig. 1A). Pretreatment of cells with the Wnt
signalling antagonist DKK-1 blocked CCN2 mediated accumulation
of b-catenin, resulting in its phosphorylation (Ser 33/37) and deg-
radation (Fig. 1B). Similarly, DKK-1 antagonised CCN-2 phosphory-
lation of GSK3b. Use of a TCF/LEF luciferase construct (Topﬂash)
conﬁrmed that CCN2 stimulated b-catenin dependent promoter
activation (Fig. 1C).
We next determined that expression of b-catenin dependent
gene products were increased by CCN2; levels of c-myc and cyclinD-1 were increased after stimulation with CCN2 (Fig. 2A). CCN2 in-
duced nuclear translocation of b-catenin was established by sub-
cellular fractionation and conﬁrmed by immunocytochemistry
(Fig. 2B and C). Mutant proteins consisting of either the N-terminal
half molecule or the C-terminal half of CCN2 were expressed and
puriﬁed and the ability to induce cytoplasmic to nuclear transloca-
tion of b-catenin was found to reside within the N-terminal half
only (Fig. 2B, lower panels).
Expression studies determined that mesangial cells expressed
the Wnt co-receptor LRP6 (data not shown). Treatment with CCN2
stimulated the phosphorylation (and subsequent internalisation)
of LRP6 on Ser 1490 suggesting that CCN2 can function as an LRP6
agonist (Fig. 3A). Pre-treatment with DKK-1/Dickkopf, blocked
CCN2 induced cell migration, but had no effect on CCN2 mediated
adhesion (Fig. 3B–D). Furthermore, siRNA knockdown of LRP6
blocked CCN2s’ pro-migratory effects. (Fig. 4A–C). Previous studies
in Xenopus embryos have shown that CCN2 interacts directly with
the LRP6 co-receptor [15] and that over expression of CCN2 results
in nuclear accumulation of b-catenin and a concurrent increase in
TCF/LEF transcription [25]. Our results here describe a functional
relationship between CCN2 and the Wnt co-receptor LRP6 (Fig. 3),
resulting in accumulation of b-catenin and promotion of the expres-
sion of downstream target genes, with clear pathogenic signiﬁcance
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human mesangial cells CCN2 modulates Wnt signalling via LRP6
through phosphorylation of its serine 1490 site resulting in nuclear
accumulation of b-catenin and TCF/LEF activity.
The pathophysiological signiﬁcance of Wnt in the progression of
nephropathy remains obscure, although recent studies have shown
that Wnt target genes are increased following obstructive injury
[8,9,26]. Human renal biopsies were collected in a multicenter
study, the European Renal cDNA Biopsy Bank (ERCB) and stratiﬁed
by the reference pathologist according to histological diagnosis.
Microarray analyses of these biopsies identiﬁed a signiﬁcant num-
ber of differentially expressed genes that are members or direct
targets of the Wnt signalling pathway including, frizzled 6, 7 and
9, dickkopf, dishevelled-1, b-catenin, TCF and myc, indicating that
Wnt activity is increased in nephropathy (Fig. 5A). These studies
suggest a correlation between increased ﬁbrosis of the kidney, loss
of kidney function, proteinuria and increased Wnt signalling activ-
ity. Microarray analysis was independently conﬁrmed and vali-
dated by Schmid et al. [27,28]. Their analyses are available for
academic use at www.nephromine.org. Preliminary studies sug-
gest that Wnt-5a and Wnt6 promote cell polarisation with marked
rearrangement of focal adhesion, tubulin and actin cytoskeletal
networks in mesangial cells. These ﬁndings illustrate a complex
and conserved nexus between the ligands of the Wnt planar polar-
ity pathway and the secondary transduction mechanism of the tra-
ditional Wnt canonical signalling pathway that is capable of
remodelling the cytoskeleton of the mesangium, with clear impli-
cations for the maintenance of actin mediated contractility during
the progression of DN.
Increased b-catenin was observed by immunohistochemistry in
kidneys from STZ-induced type 1 diabetic mice (Fig. 5B) at
27 weeks of diabetes, as well as mice that had undergone UUO at
10 days (Fig. 5B), in vivo models for hyperglycaemia and glomeru-
lar hypertension mediated damage to the kidney respectively.
Staining of b-catenin was particularly evident in the tubular epi-
thelium in diabetic kidneys (Fig. 5B). Previous studies have sug-
gested that acute exposure of cells to elevated glucose can
activate Wnt signalling [29]. Increased b-catenin was also observed
in mesangial cells cultured in 30 mM glucose or subjected to cyclic
mechanical strain (Fig. 5D), in vitro models of hyperglycemia and
hypertension, respectively. Increased expression of CCN2 during
the progression of DN, likely leads to activation of Wnt signalling
and subsequent initiation of TCF/LEF transcription; Wnt target
genes are increased in the kidney following obstructive injury
[26], while inhibition of Wnt signalling by DKK-1 leads to de-
creased expression of Wnt target genes such as C-myc, ﬁbronectin
and twist, and improved renal function following UUO and hyper-
tensive injury [30]. Pharmacological intervention has shown that
modulation of Wnt signalling via GSK 3b regulation is a potential
therapeutic target in treatment of organ hypertrophy [11] and con-
stitutes an emerging target in renal disease. CCN2 had previously
been shown to interact with the Wnt co-receptor, LRP6 [15].
Although Wnt signalling is crucially important during renal devel-
opment, evidence suggests that it may be reactivated in the setting
of renal disease. Consequently, it was suggested that CCN2 can
interact with Wnt signals in the setting of diabetic nephropathy,
thereby expanding its detrimental repertoire [31]. We propose
CCN2 antagonism as a potential therapeutic intervention is at the
centre of multiple pathways, including Wnt, that modify the path-
ogenesis and progression of diabetic nephropathy.
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